Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 7:12:5479-5489.
doi: 10.2147/CMAR.S194874. eCollection 2020.

First-Line Treatment with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research

Federica Tomao  1 , Serena Maria Boccia  2 , Carolina Maria Sassu  2 , Martina Chirra  3 , Innocenza Palaia  2 , Maria Cristina Petrella  4 , Violante Di Donato  2 , Nicoletta Colombo  1   5 , Pierluigi Benedetti Panici  2
Affiliations
Review

First-Line Treatment with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research

Federica Tomao et al. Cancer Manag Res. .

Abstract

Olaparib is currently approved in maintenance treatment of advanced ovarian cancer after response to first-line chemotherapy for breast related cancer antigens (BRCA) mutated patients. The use of this agent is based on data from SOLO1 study that observed a decreased risk of disease progression or death and a median progression-free survival about 36 months longer in case of therapy with olaparib. However, this trial recruited only patients with advanced stage ovarian cancer. The aim of this review is to retrace the available data in order to clarify the potential efficacy and feasibility of olaparib administration in newly diagnosed epithelial ovarian cancer also in early stages.

Keywords: BRCA mutation; PARPinhibitors; early stage ovarian cancer; newly diagnosed ovarian cancer; olaparib.

PubMed Disclaimer

Conflict of interest statement

Drs Nicoletta Colombo reports personal fees from Roche, Pharmamar, Astra Zeneca, Clovis, Tesaro, GSK, Pfizer, Amgen, Immunogen, and Biocad, outside the submitted work. The authors report no other conflicts of interest in this work.

References

    1. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. J Epidemiol Biostat. 2001;6(1):107–138. - PubMed
    1. Percent of cases & 5-year relative survival by stage at diagnosis: ovarian cancer. Available from: https://seer.cancer.gov/statfacts/html/ovary.html. Accessed January30, 2020.
    1. Morice P, Leblanc E, Rey A, et al. Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Société Francaise d’Oncologie Gynécologique). Hum Reprod. 2005;20(5):1379–1385. doi: 10.1093/humrep/deh777 - DOI - PubMed
    1. Tomao F, Peccatori F, Del Pup L, et al. Special issues in fertility preservation for gynecologic malignancies. Crit Rev Oncol Hematol. 2016;97:206–219. doi: 10.1016/j.critrevonc.2015.08.024 - DOI - PubMed
    1. Colombo N, Sessa C, Du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019;30(5):672–705. doi: 10.1093/annonc/mdz062 - DOI - PubMed